Potential adverse events with biologic response modifiers

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


In recent years, an explosion of biologic response modifiers has entered the market to combat a variety of immune-mediated diseases. These can be in the form of recombinant cytokines, as in the case of interferon beta in the treatment of multiple sclerosis, or novel engineered antibodies constructed by combining non-human determinants with a human immunoglobulin scaffold, as in the case of omalizumab in the treatment of allergic asthma. More recently, completely human monoclonal antibodies have also been constructed. Adverse reactions related to these agents can be classified as expected or unexpected events. A number of case studies and a handful of randomized trials have demonstrated the potential toxicities with the use of biologic response modifiers. This article aims to review adverse event profiles of select biologic response modifiers for which the most data is available and are common to a rheumatology, allergy/immunology, and dermatology patient population.

Original languageEnglish (US)
Pages (from-to)471-485
Number of pages15
JournalAutoimmunity Reviews
Issue number7
StatePublished - Aug 2006


  • Adverse events
  • Biologic response modifiers
  • Monoclonal antibodies
  • Tissue necrosis factor

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Potential adverse events with biologic response modifiers'. Together they form a unique fingerprint.

Cite this